Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349673 · ClinicalTrials.gov registry record · Phase 3
The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis
A Phase 3 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT01349673 is a Phase 3 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 114 participants.
The verdict
NCT01349673, a Phase 3 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability of cyclically-dosed rectal budesonide foam in participants with active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).
Interventions
- DRUG Budesonide Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2011-05-31 |
| Est. Completion | 2014-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349673
The ClinicalTrials.gov registry entry for NCT01349673 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Budesonide Foam is the first listed.
NCT01349673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349673 about?
NCT01349673 is a clinical study titled "The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis". The purpose of this study is to evaluate safety and tolerability of cyclically-dosed rectal budesonide foam in participants with active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).
What is the current status of trial NCT01349673?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2011-05-31. Estimated completion is 2014-12-31.
What interventions are being tested in trial NCT01349673?
The interventions under investigation include: Budesonide Foam (DRUG).
Who is sponsoring clinical trial NCT01349673?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.